Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 9 of 9« First...56789

WHO calls for fighting food borne diseases that can be deadly

At least 600 million people, or 1 in 10 worldwide, fall ill from contaminated food each year and 420,000 die, many of them young children, the World Health Organization (WHO) said on Thursday. Giving its first global estimates of preventable food borne diseases, a WHO report called on governments and industry to improve inspections and […]

Read More »

Zafgen halts obesity drug trial after second patient death

Zafgen Inc said the U.S. Food and Drug Administration was putting a late-stage study testing its experimental obesity drug on complete hold after a second patient died during the trial. The company’s shares fell 7.4 percent to $5.81 in extended trading after closing down 60 percent on Wednesday. A complete clinical hold is an order […]

Read More »

Alexion’s $550,000 bone drug too expensive for Britain

A new drug to treat a rare inherited bone disorder from Alexion Pharmaceuticals ALXN.O that costs more than $550,000 a year for each patient has been deemed too expensive by Britain’s health cost watchdog NICE. The case highlights the sky-high price of some medicines for treating rare diseases and the dilemma this poses for cash-strapped […]

Read More »

Emails Reveal Theranos CEO Sought Marine General’s Help in Skirting Federal Inquiry

PALO Alto, Calif. – Blood-testing company Theranos continues to face scrutiny following a Washington Post report that alleges the company was attempting to skirt federal law by asking a Department of Defense official to intervene in an inquiry by the U.S. Food and Drug Administration (FDA). In 2012, the Department of Defense raised concerns about […]

Read More »

Zafgen says second patient dies in obesity drug trial

A second patient died in a late-stage trial of Zafgen Inc’s experimental obesity treatment, highlighting safety concerns associated with drugs that aim to treat a condition that affects one in three Americans. Shares of Zafgen tumbled more than 50 percent to $8.00 in premarket trading on Wednesday. The company said a patient receiving its drug, […]

Read More »

Alcresta Pharmaceuticals Receives FDA Clearance for RELiZORB

First Digestive Enzyme Cartridge Designed for Patients on Enteral Feeding     December 02, 2015 07:00 AM Eastern Standard Time   NEWTON, Mass.–(BUSINESS WIRE)–Alcresta Pharmaceuticals, a specialty pharmaceutical company focused on developing innovative enzyme-based products for gastrointestinal and rare disease, today announced it received de novo approval from the U.S. Food and Drug Administration (FDA) […]

Read More »

Anavex May Have Just Become a Target for Biogen and Eli Lilly

Anavex Life Sciences Corp. (NASDAQ:AVXL) may have just emerged as a significant player in the Alzheimer’s drug market. The clinical-stage biotech company specializes in the development of treatments for currently incurable diseases. It has stumbled upon AVANEX 3-71 which is a drug candidate that may have significant potential for reduction of synaptic loss, amyloid, and […]

Read More »

Ethicists square off over editing genes in human embryos

Debate over the use of powerful new gene editing tools in human eggs, sperm and embryos grew heated on Tuesday as scientists and ethicists gathered at an international summit to discuss the technology, which has the power to change the DNA of unborn children. Several groups have already called for restrictions on use of the […]

Read More »

Walnuts each day keep the doctor away?

(Reuters Health) – Eating a handful of walnuts each day might help keep the doctor away, at least for some people who are at risk of developing diabetes, a U.S. study suggests. When people in the study added 56 grams of walnuts (2 ounces, or about 14 walnuts) to their daily diet for six months, […]

Read More »

Diagnosing malaria with a cell phone

New technology that transforms a cell phone into a mobile polarized microscope can diagnose malaria in a Rwandan village with the same level of accuracy as a hi-tech lab in a major Western city, according to Texas A&M University biomedical engineers developing the device. “The way they diagnose malaria now is with a microscope but […]

Read More »

Gilead put profit ahead of hepatitis C patients: U.S. Senate report

U.S. state Medicaid programs spent $1.3 billion before rebates in 2014 on Gilead Sciences’ new hepatitis C drugs to treat fewer than 2.4 percent of enrollees with the liver disease, according to a U.S. Senate investigation into pricing of the blockbuster medicines. In the latest salvo against high U.S. prices for important medicines, the 18-month […]

Read More »

India restores federal funding for AIDS program after criticism

India will fully fund its AIDS control program federally, the health minister said on Tuesday, restoring support months after it was criticized for slashing its contribution and asking individual states to fill the gap.   India’s globally-lauded AIDS program has been in disarray since last year due to payment delays that worsened after Prime Minister […]

Read More »

FDA Denies Approval for Repros Therapeutics’ Enclomiphene

Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene THE WOODLANDS, Texas, Dec. 1, 2015 (GLOBE NEWSWIRE) — Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application for enclomiphene for the treatment of secondary hypogonadism in […]

Read More »

Novo Nordisk A/S Breathes New Life into XOMA with $295 Million Diabetes Pact

XOMA Announces License Agreement With Novo Nordisk for XMetA Program in Diabetes Novo Nordisk acquires exclusive global rights to XMetA program for the treatment of diabetes XOMA retains commercialization rights for rare disease indications $5.0 million upfront payment Agreement includes up to $290.0 million in additional potential milestone payments XOMA is entitled to tiered royalties […]

Read More »

Where Gilead May Be a Decade from Now

FOSTER CITY, Calif. – Pharmaceutical prognosticators predict Gilead Sciences, Inc. (GILD) will remain a leader in providing therapies for hepatitis and HIV over the next decade, but also speculate the company will break ground in new treatment areas for oncology, respiratory and rheumatoid arthritis.   Contributors to The Motley Fool, an online investment news site, […]

Read More »

Page 9 of 9« First...56789

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation